Profile data is unavailable for this security.
About the company
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
- Revenue in USD (TTM)9.89bn
- Net income in USD1.29bn
- Incorporated1997
- Employees7.50k
- LocationBiogen Inc225 Binney StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (302) 351-3367
- Fax+1 (302) 636-5454
- Websitehttps://www.biogen.com/
Mergers & acquisitions
| Acquired company | BIIB:NSQ since announced | Transaction value |
|---|---|---|
| Alcyone Therapeutics Inc | 27.24% | 85.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris Inc | 14.30bn | -3.51bn | 16.73bn | 30.00k | -- | 1.14 | -- | 1.17 | -2.96 | -2.96 | 12.22 | 12.78 | 0.3634 | 2.20 | 5.44 | 476,663.30 | -8.93 | -1.35 | -10.68 | -1.61 | 39.55 | 40.86 | -24.58 | -4.18 | 0.8162 | 2.78 | 0.4948 | -- | -2.98 | 3.66 | -454.23 | -- | -7.35 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 19.37bn | 2.84k | 15.20 | 3.74 | 14.04 | 3.77 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| United Therapeutics Corp | 3.18bn | 1.33bn | 21.26bn | 1.40k | 17.39 | 2.98 | 14.97 | 6.68 | 27.90 | 27.90 | 66.48 | 162.60 | 0.4176 | 2.25 | 10.11 | 2,273,357.00 | 17.51 | 14.75 | 19.14 | 16.07 | 87.92 | 89.79 | 41.94 | 39.28 | 6.28 | -- | 0.00 | 0.00 | 10.61 | 16.50 | 11.68 | 20.99 | 54.73 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 21.26bn | 4.70k | -- | 2.45 | -- | 10.94 | -7.26 | -7.26 | 5.00 | 21.95 | 0.1468 | 4.27 | 7.17 | 413,617.00 | -21.31 | 10.19 | -25.32 | 13.43 | 70.32 | 75.74 | -145.16 | 19.02 | 3.22 | -- | 0.0684 | 0.00 | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 21.27bn | 750.00 | -- | 4.94 | -- | 1,598.09 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Royalty Pharma plc | 2.38bn | 770.95m | 26.35bn | 100.00 | 25.66 | 4.07 | 29.46 | 11.08 | 1.78 | 1.78 | 4.21 | 11.22 | 0.1257 | -- | 84.52 | 23,781,930.00 | 7.00 | 6.72 | 9.03 | 9.10 | -- | -- | 55.68 | 50.56 | -- | 7.06 | 0.4795 | 50.52 | 5.06 | 2.30 | -10.25 | 9.26 | -4.90 | 24.01 |
| Biogen Inc | 9.89bn | 1.29bn | 27.60bn | 7.50k | 21.36 | 1.51 | 13.32 | 2.79 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 15.98m | 10.89% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 14.76m | 10.06% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 8.73m | 5.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 7.16m | 4.88% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 6.94m | 4.73% |
| Geode Capital Management LLCas of 31 Dec 2025 | 4.20m | 2.86% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 3.49m | 2.38% |
| Point72 Asset Management LPas of 31 Dec 2025 | 2.81m | 1.92% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 2.64m | 1.80% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025 | 2.11m | 1.44% |
